PRISM Biolabs

Ownership

Private

Employees

~50

Stage

Preclinical

Modalities

Small molecule

PRISM Biolabs General Information

Developing peptide-acting small molecules using their PepMetics platform technology. Recently entered into a collaboration with Eli Lilly.

Contact Information

Website

Primary Industry

Biotech

Corporate Office

Fujisawa,
Japan

Drug Pipeline

No pipeline data available

For full access to PRISM Biolabs's pipeline data

Key Partnerships

Eli Lilly

Need more data on over 80,000 life science companies, including over 1200 biotechs?

PRISM Biolabs Funding

Deal Type	Date	Amount	Status	Stage

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view PRISM Biolabs's complete valuation and funding history, request access »